499 assets in Hepatocellular Carcinoma

Therapeutic assets addressing Hepatocellular Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ect204 t cells Hepatocellular Carcinoma	Eureka Therapeutics Inc.	P1/2	CC (41)
Epcam Car-T Hepatocellular Carcinoma	Zhejiang University	P1	CC (41)
eu307 car-t cell Hepatocellular Carcinoma	Eutilex	P1	CC (41)
fb-1603 Hepatocellular Carcinoma	Febico Biomedical Corp.	P1/2	CC (41)
fhb7h3.car-ts Hepatocellular Carcinoma	The Affiliated Hospital of Xuzhou Medical University	P1/2	CC (41)
Gene Modified Anti-Il1Rap Chimeric Antigen Receptor T Cells :2.5&#X00D7;10^8 Hepatocellular Carcinoma	Shanghai Zhongshan Hospital	P1	CC (41)
gpc3 car-t cells Hepatocellular Carcinoma	Shenzhen University General Hospital	P1	CC (41)
her2bbζ/cd19t+ t cells Hepatocellular Carcinoma	Shanghai Public Health Clinical Center	P1/2	CC (41)
H-Gamma1 Heavy Chain Humanized (1-449) [Vh (Homo Sapiens Ighv3-2301 (81.6%) -(Ighd) -Ighj302 (91.7%) M123>T (114), Cdr-Imgt [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo Sapiens Ighg103V (100%) G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14 (Ch1 R120>K (216) (120-217), Hinge 1-15 (218-232), Ch2 (233-342), Ch3 E12 (358), M14 (360) (343-447), Chs (448-449)) (120-449)], (222-218')-Disulfide With L-Kappa Light Chain Humanized (1'-218') [Vkappa (Homo Sapiens Igkv1-3301 (87.8%) -Igkj401 (100%), Cdr-Imgt [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo Sapiens Igkc01 (100%) Km3 A45.1, V101 (C-Kappaa45.1 (157'), V101 (195')) (112'-218')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa Hepatocellular Carcinoma	Genentech, Inc.	P1	CC (41)
Human Vascular Endothelial Growth Factor Receptor 1 (Vegfr-1) Fragment 129-228 Comprising The Second Extracellular Domain Of The Vegf Receptor (Vegfr-D2), [N<Sup>196</Sup>>A<Sup>68</Sup>]-Variant, Anti-(Human Vascular Endothelial Growth Factor (Vegf) (1-100 In The Current Sequence) Fused, Via A (G4S)3 Peptide Linker (101-115), To Gamma 1 Heavy Chain (116-563) [Vh (Homo Sapiens Ighv3-2304 -(Ighd) -Ighj401, Cdr-Kabat [5.17.9] (146-150.165-181.214-222)) (116-233) -Homo Sapiens Ighg103 (Ch1 (234-331), Hinge (332-346), Ch2 S<Sup>414</Sup>>A, E<Sup>449</Sup>>A, K<Sup>450</Sup>>A (347-456), Ch3 (457-561), Chs (562-563)) (234-563)], (336-214')-Disulfide With Kappa Light Chain (1'-214') [V-Kappa (Homo Sapiens Igkv1-1201 -Igkj101, Cdrkabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (108'-214')]; Dimer (342-342'', 345-345'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa Hepatocellular Carcinoma	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P1	CC (41)
imm27m Hepatocellular Carcinoma	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P1	CC (41)
jk08 Hepatocellular Carcinoma	Salubris Biotherapeutics Inc	P1/2	CC (41)
Kat-101 Hepatocellular Carcinoma	Primocure Pharma	P1/2	CC (41)
Kat-201 Hepatocellular Carcinoma	Primocure Pharma	P1/2	CC (41)
LXP1788 Hepatocellular Carcinoma	LaunXP Biomedical Co., Ltd.	P1	CC (41)
mrg006a Hepatocellular Carcinoma	Lepu Biopharma Co., Ltd.	P1/2	CC (41)
mts105 Hepatocellular Carcinoma	Shen Lin	P1	CC (41)
Ori-C101 Hepatocellular Carcinoma	OriCell Therapeutics Co., Ltd.	P1/2	CC (41)
Oric902 Hepatocellular Carcinoma	Peking University	P1	CC (41)
Otx-2002 Hepatocellular Carcinoma	Omega Therapeutics	P1/2	CC (41)
Pebezertinib Hepatocellular Carcinoma	Blueprint Medicines Corporation	P1	CC (41)
rz-001 Hepatocellular Carcinoma	Rznomics, Inc.	P1/2	CC (41)
Second Generation 4-1Bbζ B7H3-Egfrt-Dhfr Hepatocellular Carcinoma	Seattle Children's Hospital	P1	CC (41)
Second Generation 4-1Bbζ Egfr806-Egfrt Hepatocellular Carcinoma	Seattle Children's Hospital	P1	CC (41)
Second Generation 4-1Bbζ Egfr806-Egfrt And A Second Generation 4 1Bbζ Cd19-Her2Tg Hepatocellular Carcinoma	Seattle Children's Hospital	P1	CC (41)
Super Car-T Hepatocellular Carcinoma	Guangzhou FineImmune Biotechnology Co., LTD.	P1	CC (41)
t3011 Hepatocellular Carcinoma	ImmVira Pharma Co. Ltd	P1/2	CC (41)
T-Ace Oil Hepatocellular Carcinoma	T-ACE Medical Co., Ltd	P1/2	CC (41)
tb511 Hepatocellular Carcinoma	Twinpig Biolab, Inc.	P1/2	CC (41)
Tgi-5 Hepatocellular Carcinoma	Hefei TG ImmunoPharma Co., Ltd.	P1	CC (41)
tqb2223 Hepatocellular Carcinoma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1	CC (41)
tqb2618 Hepatocellular Carcinoma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1	CC (41)
tt-4 Hepatocellular Carcinoma	Tarus Therapeutics, Inc.	P1/2	CC (41)
Tumor Antigen Loaded Autologous Dendritic Cells Hepatocellular Carcinoma	West China Hospital	P1	CC (41)
Valemetostat Hepatocellular Carcinoma	University of Alabama at Birmingham	P1/2	CC (41)
br2008 Hepatocellular Carcinoma	Boryung Pharmaceutical Co., Ltd	P1	CC (40)
br2008-1 Hepatocellular Carcinoma	Boryung Pharmaceutical Co., Ltd	P1	CC (40)
Perflutren Lipid Microsphere Intravenous Suspension Hepatocellular Carcinoma	The First Hospital of Jilin University	P1	CC (40)
Anti-Glypican 3/Cd3 Bispecific Antibody Ery974 Hepatocellular Carcinoma	Chugai Pharmaceutical	P1	C (39)
Ateganosine Hepatocellular Carcinoma	University of Texas Southwestern Medical Center	Early P1	C (39)
Cba-1205 Hepatocellular Carcinoma	Chiome Bioscience Inc.	P1	C (39)
Crpa1A2 Hepatocellular Carcinoma	Corregene Biotechnology Co., Ltd	P1	C (39)
Ctx-10726 Hepatocellular Carcinoma	Compass Therapeutics	P1	C (39)
Exemestane Hepatocellular Carcinoma	SAPU NANO (US) LLC	P1	C (39)
JS014 Hepatocellular Carcinoma	Xiangya Hospital of Central South University	P1	C (39)
Sapu003 Hepatocellular Carcinoma	SAPU NANO (US) LLC	P1	C (39)
st-01156 Hepatocellular Carcinoma	SEED Therapeutics, Inc.	P1	C (39)
Tc-G203 Cells Treatment Hepatocellular Carcinoma	Beijing GoBroad Hospital	Early P1	C (39)
xh001 Hepatocellular Carcinoma	Shenzhen Xinhe Biomedical	P1	C (39)
BO-112 Hepatocellular Carcinoma	Jonsson Comprehensive Cancer Center	Early P1	C (38)

Showing 351 to 400 of 499 assets

PreviousPage 8 of 10Next